Cogle CR - Search Results

1

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes.

Drusbosky LM, Cogle CR. Drusbosky LM, et al. Among authors: cogle cr. Curr Hematol Malig Rep. 2017 Oct;12(5):478-483. doi: 10.1007/s11899-017-0412-z. Curr Hematol Malig Rep. 2017. PMID: 28913766 Free PMC article. Review.

2

Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.

Cogle CR, Imanirad I, Wiggins LE, Hsu J, Brown R, Scornik JC, Wingard JR. Cogle CR, et al. Clin Adv Hematol Oncol. 2010 Jan;8(1):40-6. Clin Adv Hematol Oncol. 2010. PMID: 20351682

3

Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.

Cogle CR, Craig BM, Rollison DE, List AF. Cogle CR, et al. Blood. 2011 Jun 30;117(26):7121-5. doi: 10.1182/blood-2011-02-337964. Epub 2011 Apr 29. Blood. 2011. PMID: 21531980 Free PMC article.

4

Radiation alone for solid tumors and the questionable development of therapy-related myelodysplastic syndromes.

Cogle CR. Cogle CR. J Natl Cancer Inst. 2014 Mar;106(3):dju025. doi: 10.1093/jnci/dju025. Epub 2014 Feb 27. J Natl Cancer Inst. 2014. PMID: 24577814 No abstract available.

5

Fishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: Need for more resources.

Cogle CR. Cogle CR. Cancer. 2014 Jun 1;120(11):1614-6. doi: 10.1002/cncr.28638. Epub 2014 Mar 18. Cancer. 2014. PMID: 24643687 Free article. No abstract available.

6

Incidence and Burden of the Myelodysplastic Syndromes.

Cogle CR. Cogle CR. Curr Hematol Malig Rep. 2015 Sep;10(3):272-81. doi: 10.1007/s11899-015-0269-y. Curr Hematol Malig Rep. 2015. PMID: 26134527 Free PMC article. Review.

7

Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.

Drusbosky L, Gars E, Trujillo A, McGee C, Meacham A, Wise E, Scott EW, Cogle CR. Drusbosky L, et al. Among authors: cogle cr. Leuk Res. 2015 Sep;39(9):984-9. doi: 10.1016/j.leukres.2015.05.015. Epub 2015 Jul 2. Leuk Res. 2015. PMID: 26189107 Free PMC article.

8

Bone marrow niche in the myelodysplastic syndromes.

Cogle CR, Saki N, Khodadi E, Li J, Shahjahani M, Azizidoost S. Cogle CR, et al. Leuk Res. 2015 Oct;39(10):1020-7. doi: 10.1016/j.leukres.2015.06.017. Epub 2015 Jul 14. Leuk Res. 2015. PMID: 26276090 Review.

9

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.

Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, Cogle CR, Edenfield WJ, Hetzer J, Kumar K, Laille E, Shi T, MacBeth KJ, Skikne B. Garcia-Manero G, et al. Among authors: cogle cr. Leukemia. 2016 Apr;30(4):889-96. doi: 10.1038/leu.2015.265. Epub 2015 Oct 7. Leukemia. 2016. PMID: 26442612 Free PMC article. Clinical Trial.

10

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Cogle CR, Scott BL, Boyd T, Garcia-Manero G. Cogle CR, et al. Oncologist. 2015 Dec;20(12):1404-12. doi: 10.1634/theoncologist.2015-0165. Epub 2015 Oct 13. Oncologist. 2015. PMID: 26463870 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146 results

Search Page

Filters